The company is also developing LTX-608, a nafamostat formulation for direct IV infusion for indications including antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as pre-filled syringe product candidates. The FDA approved reducing the NEPHRO CRRT clinical study from 166 to 70 patients with 90% power, and the company activated clinical study sites targeting completion by year-end 2025.
Cyborg Score Rationale
Talphera operates in clinical-stage development with promising lead candidate but faces typical biotech execution risks. Recent FDA approval for study optimization and improved cash management are positive, though the company experienced significant shareholder dilution from its rebranding (formerly AcelRx) and operates with limited cash runway.
Top Insights
FDA approved reducing NEPHRO CRRT study size to 70 patients while maintaining 90% statistical power for primary endpoint
Company secured multi-tranche financing of up to $14.8 million with first tranche closed in April 2025
Q2 2025 net loss of $3.5M improved from $3.8M in Q2 2024; operating expenses declined to $3.7M from $4.3M YoY
Rebranded from AcelRx Pharmaceuticals in January 2024 to Talphera, reflecting strategic pivot to nafamostat-focused platform
Named Competitors
Apixaban — Direct oral anticoagulant for various indications
Heparin-based anticoagulants — Standard anticoagulation for CRRT and extracorporeal circuits
Remdesivir — Antiviral for severe respiratory infections
Recent Developments
(August 2025) Reported Q2 2025 results with improved financials and 15 patients enrolled in NEPHRO registrational study
(April 2025) Closed first tranche of $14.8M multi-tranche financing led by existing investors
(Early 2025) FDA approval to reduce NEPHRO CRRT study from 166 to 70 patients while maintaining statistical power
(January 2024) Completed rebrand from AcelRx Pharmaceuticals to Talphera, Inc.
Open the full interactive Talphera, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.